SHANGHAI GENTECH CO LTD

Shanghai Gentech’s flat stock, 27% slump, and weak volume reveal a biotech giant losing investor confidence despite a 14.9bn CNY market cap and bold GMO ambitions.

Shanghai Gentech’s flat trading session amid tech sector volatility highlights a potential rebound driven by its biotech diversification and sustainable innovation focus.